Benzodiazepine use and expenditures for Medicare beneficiaries and the implications of Medicare Part D exclusions.
Benzodiazepine use and expenditures for Medicare beneficiaries and the implications of Medicare Part D exclusions.
复制标题
医疗保险受益人苯二氮卓类药物的使用和支出以及医疗保险 D 部分排除的影响。
DOI：
10.1176/ps.2008.59.4.384
复制
发表时间：
2008
期刊：
影响因子：
--
通讯作者：
Stuart,Bruce
中科院分区：
文献类型：
--
作者：
Yang,Hui-wenKeri;Simoni-Wastila,Linda;Zuckerman,IleneH;Stuart,Bruce
ObjectivesBenzodiazepines are excluded from prescription drug cov-erage under Medicare Part D. The objectives of this study were twofold: to provide national estimates of benzodiazepine utilization and expenditure patterns and to examine the impact of drug coverage and other factors associated with utilization of benzodiazepines and potential benzodiazepine substitute classes.MethodsThe 2002 Medicare Current Beneficiary Survey provided national estimates of benzodiazepine use and expenditures among Medicare beneficiaries. Multivariate logistic regression was conducted to assess the relationships between independent variables and use of benzodiazepines and potential substitute classes. The independent variable of interest was drug coverage, assessed by payer source. Other covariates included in the models were chronic conditions associated with benzodiazepine use, age, sex, race, and income.ResultsIn 2002, 13.7% of Medicare beneficiaries received at least one benzodiazepine fill, with an average of 5.8 benzodiazepine prescriptions filled at an annual cost of $190. Specific sources of prescription drug coverage were not significantly associated with benzodiazepine use. Female gender, chronic mental illness, age under 65, and lower income were significantly positively associated with benzodiazepine use in the Medicare population, whereas black and other races were significantly negatively associated with benzodiazepine use in this population. Compared with Medicare beneficiaries without supplemental drug coverage, beneficiaries with supplemental drug coverage were more likely to use potential benzodiazepine substitute classes than benzodiazepines.ConclusionsBenzodiazepines were widely used by Medicare beneficiaries. Drug coverage influences access to benzodiazepines and potential substitute classes. These findings have important implications for identifying beneficiaries potentially affected by the exclusion of benzodiazepine coverage under Medicare Part D.(Psychiatric Services 59: 384–391, 2008)
